Table 3.
Treatment received and response to neoadjuvant therapy. Abbreviations: mTP53, mutated TP53; NA, not available; NAC, neoadjuvant chemotherapy.
| Characteristic | No of Patients (%) |
P | |
|---|---|---|---|
| mTP53 group (N = 41) | Control group (N = 82) | ||
| Chemotherapy | 0.366a | ||
| Neoadjuvant | 15 (36.6%) | 30 (36.6%) | |
| Adjuvant | 16 (39%) | 41 (50%) | |
| No chemotherapy | 9 (21.9%) | 11 (13.4%) | |
| NA | 1 (2.4%) | 0 (0%) | |
| Chemotherapy regimen | 0.556a | ||
| Anthracycline and taxane-based | 19 (65.5%) | 53 (74.6%) | |
| Taxane-based | 9 (31%) | 15 (21.1%) | |
| Anthracycline-based | 1 (3.4%) | 3 (4.2%) | |
| Response to NAC | n = 15 | n = 30 | 0.700a |
| Complete response | 5 (33.3%) | 11 (36.7%) | |
| Partial response | 10 (66.7%) | 15 (50%) | |
| Stable disease | 0 (0%) | 3 (10%) | |
| Progressive disease | 0 (0%) | 1 (3.3%) | |
| Type of breast surgery | 0.436a | ||
| Breast-conserving surgery | 19 (46.3%) | 45 (54.9%) | |
| Mastectomy | 20 (48.8%) | 34 (41.5%) | |
| NA | 2 (4.9%) | 3 (3.7%) | |
| Adjuvant radiotherapy | 26 (63.4%) | 77 (93.9%) | <0.001a |
a
Fisher exact test.